Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May;61(5):549-551.
doi: 10.1002/mus.26871. Epub 2020 Apr 4.

Rituximab for chronic inflammatory demyelinating polyneuropathy-A potential therapeutic option

Joss C Cohen  1 , Richard A Lewis  1
Affiliations
Editorial

Rituximab for chronic inflammatory demyelinating polyneuropathy-A potential therapeutic option

Joss C Cohen et al. Muscle Nerve. 2020 May.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status. J Peripher Nerv Syst. 2010;15:326-333.
    1. Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory polyneuropathy. Muscle Nerve. 2020. https://doi.org/10.1002/mus.26804.
    1. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001;40:205-211.
    1. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286-293.
    1. Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217-2225.

MeSH terms

LinkOut - more resources